NantHealth (NH) Tops Q4 EPS by 1c, Revenues Miss

NantHealth (NASDAQ: NH) reported Q4 EPS of ($0.08), $0.01 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $22.9 million versus the consensus estimate of $23.07 million.

• Total Revenue in Q4 was $22.9 Million
  • SaaS revenue of $17.3 million in Q4, up 9% from Q3
• Enhanced efficiencies continued to drive significantly lower operating expenses in both Q4 and full year of 2018
• For 2018, substantially improved adjusted Non-GAAP bottom line results
• Sequencing and Molecular Analysis, 1,021 total tests ordered in Q4, including 539 GPS Cancer® and 482 Liquid GPS℠ Tests; continued sequential quarterly growth in total tests ordered

“Our financial results over 2018 reflect continued overall progress to our business,” said Bob Petrou, Interim Chief Financial Officer of NantHealth. “On a sequential quarterly basis, we grew revenue, significantly lowered total operating expenses and reduced our cash burn. We are particularly pleased with the growth of our entire SaaS business. Looking ahead, our well-developed sales pipeline bodes well for the company’s topline, and our entire team is focused on further growing the business, managing costs and driving meaningful improvement in our financial performance.”

For earnings history and earnings-related data on NantHealth (NH) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Optimum Communications gets NYSE non-compliance notice over stock price
• Diana Shipping drops bid for Genco after price demands spike to $36.91